Collectively, treatment of cisplatin resistant sublines with DEAB significantly depleted an ALDH1+ve CSC subset, thereby sensitizing chemoresistant NSCLC cells to the cytotoxic effects of cisplatin. This evidence concerns the gene ALDH1A1 and non-small cell lung carcinoma.